Trial Profile
Efficacy of Atomoxetine for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents and Young Adults With Substance Use Disorders (SUD)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 19 Nov 2012
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 29 Sep 2010 Trial has been discontinued due to poor patient accrual.
- 29 Sep 2010 New trial record